Plasencia C, Rooney P H, Taron M, Martinez-Balibrea E, McLeod H L, Abad A
Medical Oncology Service and Laboratory of Molecular Biology, Hospital Universitari Germans Trias i Pujol, Ctra del Canyet s/n, 08916 Badalona, Barcelona, Spain.
Int J Oncol. 2003 May;22(5):945-53. doi: 10.3892/ijo.22.5.945.
Thymidylate synthase (TS), a critical enzyme in the de novo synthesis of thymidylate, is an important target for fluoropyrimidines and folate-based TS inhibitors. Overexpression of TS has been correlated to 5-fluorouracil (5FU)-resistance. Because 5FU still remains a basic component of the treatment of colorectal cancer, circumvention of resistance is of vital importance. A panel of sensitive (HT29 and LoVo) and 5FU-resistant colorectal cancer cell lines (HT29-5FUR and LoVo-5FUR) were subjected to comparative genomic hybridization (CGH) analysis to identify possible amplified/deleted regions associated with 5FU-resistance in colon tumours. We have identified chromosomal gains at 5p, 6, 7p, 7q and 8q and one loss at 3q in 5FU-resistant cells as compared to corresponding sensitive cell lines. Neither chromosomal gains at 18p nor gene amplification of TS were observed in our resistant cell lines although an overexpression of TS gene exists (at mRNA level) in these cell lines as compared with corresponding parental cells. Most of the chromosomal gains identified in this study occur frequently in sporadic colorectal tumours and has been associated to a poor prognosis and a greater progression of the tumour and could be related to a worse chemotherapy response. The chromosomal imbalance profile detected in 5FU-resistant cell lines should provide a basis for interpreting mechanisms of 5FU-resistance in colorectal cancer and also possibly in other tumours treated with this agent. This study also identified new genes potentially implicated in 5FU-resistance and suggests new targets that could be useful for the chemotherapy treatment of colorectal cancer.
胸苷酸合成酶(TS)是胸苷酸从头合成中的关键酶,是氟嘧啶和基于叶酸的TS抑制剂的重要作用靶点。TS的过表达与5-氟尿嘧啶(5FU)耐药相关。由于5FU仍是结直肠癌治疗的基本组成部分,克服耐药性至关重要。一组敏感的(HT29和LoVo)及5FU耐药的结直肠癌细胞系(HT29-5FUR和LoVo-5FUR)接受了比较基因组杂交(CGH)分析,以确定与结肠肿瘤中5FU耐药相关的可能的扩增/缺失区域。与相应的敏感细胞系相比,我们在5FU耐药细胞中鉴定出5号染色体短臂、6号、7号染色体短臂、7号染色体长臂和8号染色体长臂的染色体增加以及3号染色体长臂的一处缺失。在我们的耐药细胞系中未观察到18号染色体短臂的染色体增加或TS基因扩增,尽管与相应的亲本细胞相比,这些细胞系中存在TS基因过表达(在mRNA水平)。本研究中鉴定出的大多数染色体增加在散发性结直肠肿瘤中频繁出现,并与预后不良和肿瘤进展更大相关,可能与化疗反应较差有关。在5FU耐药细胞系中检测到的染色体不平衡图谱应为解释结直肠癌以及可能接受该药物治疗的其他肿瘤中5FU耐药的机制提供依据。本研究还鉴定出可能与5FU耐药相关的新基因,并提出了可能对结直肠癌化疗治疗有用的新靶点。